Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-12-19, 09:18:41 | version 1.38.0
DENTALTRIBUNE The World’s Dental Newspaper · Asia Pacific Edition Published in Hong Kong www.dental-tribune.asia Vol. 14, No. 12 ANTIBIOTICS A short interview with Dr Paul Sambrook, Australia, about what dental professionals can do to combat the growing issue of re- sistance. ROOTS SUMMIT Stephen Jones & Drs David E. Jaramillo and Freddy Belliard re- view this year’s most important event in endodontics. GINGIVAL AESTHETICS Dr Jiro Abe & Kyoko Kokubo, Japan, explain how to optimise conventional dentures with an innovative veneering material. ” Page 3 ” Page 8 ” Page 14 By DTI MELBOURNE, Australia: After re- searching the development of a vaccine for chronic periodontitis for the past 15 years, a team of sci- entists from the Oral Health CRC at the University of Melbourne has published their latest findings. The results thus far show promis- ing prospects that the vaccine may reduce the need for surgery and antibiotics for patients with severe periodontal disease. Ac- cording to the researchers, clinical trials could potentially begin on periodontitis patients in 2018. “Periodontitis is widespread and destructive. We hold high hopes for this vaccine to improve the quality of life of millions of people,” said Prof. Eric Reynolds, CEO of the Oral Health CRC. Developed in collaboration with Australian biopharmaceutical com- pany CSL Limited, the vaccine targets enzymes produced by the bacterium Porphyromonas gingi- valis, one of the main periodontal pathogens, triggering an immune response. According to the re- searchers, this response produces antibodies that neutralise the pathogen’s destructive toxins. Currently, periodontitis is treated by manually removing toxic plaque that builds up be- tween the tooth and the gingivae, which sometimes involves sur- gery and antibiotic regimes. Al- though these measures are help- ful, in many cases the bacterium re-establishes itself in the dental plaque, which causes a microbio- logical imbalance, so the disease continues, Reynolds said. Epidemiological surveys indi- catethatmoderatetosevereforms of periodontitis affect about one in three adults worldwide. Left un- treated, the condition can result in the destruction of gingival tissue and ultimately in tooth loss. Several studies have further linked the disease to an increased risk of various health conditions, including cardiovascular diseases, certain cancers, preterm birth and dementia. If implemented in clin- ical practise, an effective vaccine for chronic periodontitis could therefore help combat the global burden of these widespread dis- eases as well. The results of the study were published in the NPJ Vaccines jour- nal on 1 December in an article, ti- tled“AtherapeuticPorphyromonas gingivalis gingipain vaccine in- duces neutralising IgG1 antibodies that protect against experimental periodontitis”. www.ivoclarvivadent.com Ivoclar Vivadent AG Bendererstr. 2 | FL-9494 Schaan | Liechtenstein | Tel.: +423 / 235 35 35 | Fax: +423 / 235 33 60 Healthy teeth produce a radiant smile. We strive to achieve this goal on a daily basis. It inspires us to search for innovative, economic and esthetic solutions for direct filling procedures and the fabrication of indirect, fixed or removable restorations, so that you have quality products at your disposal to help people regain a beautiful smile. Distinguished by innovation IV_Image_Anz_102x128_Layout 1 01.12.11 17:10 Seite 1 AD (866) 999-2635 AD First dental vaccine may help combating chronic periodontitis soon Flow cytometry is used to measure changing levels of oral bacteria. © Oral Health CRC/University of Melbourne © Claudia Duschek/DTI Bendererstr. 2 | FL-9494 Schaan | Liechtenstein | Tel.: +423 / 2353535 | Fax: +423 / 2353360 IV_Image_Anz_102x128_Layout 101.12.1117:10 Seite 1